Getting your player ready...
A much cheaper drug has proved just as good as a $2,000 monthly shot at treating a common eye disorder — wet macular degeneration — that can lead to blindness, a long-awaited study has found. It also shows that patients can be treated less often, sparing them a lot of pain and expense. Vision improvement after one year was the same for patients given $50 shots of Avastin or the pricier Lucentis, the 1,200-patient study found. It was published online Thursday by the New England Journal of Medicine.
